title: Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer.
authors.forename: J
authors.initials: J
authors.lastname: Waxman
authors.forename: A
authors.initials: A
authors.lastname: Man
authors.forename: W F
authors.initials: WF
authors.lastname: Hendry
authors.forename: H N
authors.initials: HN
authors.lastname: Whitfield
authors.forename: G M
authors.initials: GM
authors.lastname: Besser
authors.forename: R C
authors.initials: RC
authors.lastname: Tiptaft
authors.forename: A M
authors.initials: AM
authors.lastname: Paris
authors.forename: R T
authors.initials: RT
authors.lastname: Oliver
mesh_terms: D000368:Aged; D002064:Buserelin / Q000009:adverse effects* / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000473:pathology*; D017329:Triptorelin Pamoate
chemical_list: D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D002064:Buserelin